{"nctId":"NCT00576251","briefTitle":"TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension","startDateStruct":{"date":"2007-10"},"conditions":["Ocular Inflammation Associated With Blepharaconjunctivitis"],"count":221,"armGroups":[{"label":"Tobramycin 0.3%/Dexamethasone 0.05%","type":"EXPERIMENTAL","interventionNames":["Drug: Tobramycin 0.3%/Dexamethasone 0.05%"]},{"label":"TOBRADEX","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TOBRADEX"]}],"interventions":[{"name":"Tobramycin 0.3%/Dexamethasone 0.05%","otherNames":[]},{"name":"TOBRADEX","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ocular inflammation associated with blepharaconjunctivitis\n\nExclusion Criteria:\n\n* ocular allergy\n* ocular disorders that would preclude safe administration of test article","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4)","description":"Microbiological success was declared if the pre-therapy pathogens were eradicated at the Exit Visit; conversely, microbiological failure was declared if pre-therapy pathogens persisted at the exit visit. The microbiological outcomes were calculated based on an algorithm that assessed whether pre-therapy pathogens were eradicated or persisted as demonstrated by comparative characterization of recovered bacteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"94.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":109},"commonTop":[]}}}